Status: Recruiting
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Participants needed: 160
Trial details
Age: 18+Biological sex: MaleType: InterventionalSponsor: Sahlgrenska University HospitalUpdated: Mar 27, 2026Locations: 1
Eligibility criteria
Patients ≥18 years undergoing an open or minimally invasive primary retroperiton... [+2]
Previous chemotherapy (including adjuvant chemotherapy at diagnosis) [+2]